PRIMO 2023 | Current treatment options for NSCLC without driver mutations

Luis Raez, MD, FACP, FCCP, Memorial Healthcare System, Pembroke Pines, FL, discusses approaches to treating non-small cell lung cancer (NSCLC) without targetable mutations. Trials such as the KEYNOTE-189 (NCT02578680) and IMpower150 (NCT02366143) studies have demonstrated the efficacy of pembrolizumab or atezolizumab plus chemotherapy, respectively. Tremelimumab plus durvalumab, which was assessed in the Phase III POSEIDON study (NCT03164616), and cemiplimab have additionally given clinicians more choices in potential treatment regimens. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.